EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Lifecycle Continuity Through Regulatory Compliance: A Comparative Evaluation of Post-Approval Change Strategies for APIs and Drug Products Under the Regulatory Frameworks of Saudi Arabia, the United States, Australia, and Eurasia

Sharlee Krunalkumar Shah, Vinit Movaliya, Zuki Patel, Maitreyi Zaveri, Akshita Parekh, Niranjan Kanaki

International Journal of Drug Regulatory Affairs · 15.06.2026 · 14 (2) · 54-59

DOI: 10.22270/ijdra.v14i2.891 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Regulatory Affairs, online erschienen am 15.06.2026. Verfasst von Sharlee Krunalkumar Shah und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The paper presents a parallel assessment of after-clearance change demands for drug substances between the regulatory structures of Saudi Arabia, US, Australia, and the Eurasian Economic Union. The regulatory structures that steer these changes in each area are fundamental for the upkeep of drug safety, usefulness, and standards as healthcare advances. The research strategy calls for a careful study of relevant standards, rules, and case assessments from all named realms. Key aspects such as the nature of amendments, data demands, clearance pathways, and treatment schedules are analyzed to understand the challenges of regulatory adherence. Added to that, the effect of these demands on market ventures, advancement, and access to treatments has been evaluated. Conclusion: In conclusion, The Review also explain that this comparative analysis demonstrates that while Saudi Arabia, US, FDA, Australia, and Eurasian Economic Union regulations on API and drug product post-approval change management are all risk-based and critical to continued safety, efficacy, and quality, these regulations also vary with respect to classification, data, and timelines.

Zitieren

APA

Shah, S. K., Movaliya, V., Patel, Z., Zaveri, M., Parekh, A., & Kanaki, N. (2026). Lifecycle Continuity Through Regulatory Compliance: A Comparative Evaluation of Post-Approval Change Strategies for APIs and Drug Products Under the Regulatory Frameworks of Saudi Arabia, the United States, Australia, and Eurasia. International Journal of Drug Regulatory Affairs, 14(2), 54-59. https://doi.org/10.22270/ijdra.v14i2.891

Vancouver

Shah SK, Movaliya V, Patel Z, Zaveri M, Parekh A, Kanaki N. Lifecycle Continuity Through Regulatory Compliance: A Comparative Evaluation of Post-Approval Change Strategies for APIs and Drug Products Under the Regulatory Frameworks of Saudi Arabia, the United States, Australia, and Eurasia. International Journal of Drug Regulatory Affairs. 2026;14(2):54-59. doi:10.22270/ijdra.v14i2.891

BibTeX
@article{Shah2026,
  author = {Shah, Sharlee Krunalkumar and Movaliya, Vinit and Patel, Zuki and Zaveri, Maitreyi and Parekh, Akshita and Kanaki, Niranjan},
  title = {Lifecycle Continuity Through Regulatory Compliance: A Comparative Evaluation of Post-Approval Change Strategies for APIs and Drug Products Under the Regulatory Frameworks of Saudi Arabia, the United States, Australia, and Eurasia},
  journal = {International Journal of Drug Regulatory Affairs},
  year = {2026},
  volume = {14},
  number = {2},
  pages = {54--59},
  doi = {10.22270/ijdra.v14i2.891}
}
Kostenlos starten →